Serbousek Jon Carl
Known title: CEOCIK: 0001536875
Serbousek Jon Carl's purchase track record
Serbousek Jon Carl has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/18/2021 | OFIX | $52K | +7.9% | -9.3% | -17.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OFIX | ▼ Sell | Tax Withholding | 6,141 | $103K | 4/3/2023 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 5,142 | $111K | 2/1/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 40,764 | $0 | 1/5/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 45,872 | $0 | 1/5/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 81,967 | $0 | 1/5/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 45,872 | $0 | 1/5/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 40,764 | $0 | 1/5/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 81,967 | $0 | 1/5/2023 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 2,369 | $38K | 11/1/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 1,450 | $33K | 8/5/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 3,899 | $129K | 4/1/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 2,041 | $67K | 4/1/2022 | View on chart |
| OFIX | ▲ Buy | Grant | 81,967 | $0 | 2/1/2022 | View on chart |
| OFIX | ▲ Buy | Open Market | 1,670 | $52K | 11/18/2021 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 2,369 | $87K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives
Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.